Does Affinity Health Plan Cover Dupixent?

What Is Dupixent and Why Does Coverage Status Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the interleukin-4 receptor alpha subunit, simultaneously inhibiting IL-4 and IL-13 signaling. The FDA first approved it in March 2017 for adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies. 1 Since then, the agency has granted six additional indications, making dupilumab one of the most broadly licensed biologics in dermatology and allergy/immunology.

Why the Indication Matters to Your Claim

Affinity Health Plan ties coverage directly to the specific FDA-approved indication on file. A claim submitted under an off-label diagnosis code will be denied regardless of clinical rationale. Confirm with your prescribing physician that the ICD-10 code on the prior-authorization request matches an approved indication before submitting paperwork.

The Cost Without Coverage

Without insurance or assistance, Dupixent costs approximately $3,400 to $4,200 per month at most U.S. Retail pharmacies. Over a year, that totals roughly $41,000 to $50,000, making authorization essentially non-negotiable for most patients. The high price point is partly why payers like Affinity require documented step therapy before approving the biologic. 2

Affinity Health Plan's Product Lines

Affinity Health Plan operates in New York State across four main product lines: Medicaid Managed Care, Child Health Plus, the Essential Plan (state-subsidized), and Qualified Health Plans sold on NY State of Health. Coverage rules for Dupixent differ slightly across these lines, particularly for Medicaid versus commercial members, because New York Medicaid has its own preferred drug list and prior authorization criteria managed through eMedNY.

FDA-Approved Indications Affinity Is Most Likely to Cover

Affinity Health Plan covers Dupixent when the prescriber documents a qualifying FDA-approved indication. The six indications most commonly submitted are listed below, along with the minimum age and dosing context the FDA label requires. 3

Atopic Dermatitis

The original indication. The FDA label permits use in patients aged 6 months and older with moderate-to-severe disease inadequately controlled by topical prescription therapies. Affinity typically requires documentation of at least one topical corticosteroid (mid-to-high potency) and at least one topical calcineurin inhibitor (tacrolimus or pimecrolimus) tried for a minimum of 8-12 weeks each, unless contraindicated.

Clinical evidence supporting this requirement is substantial. In the SOLO 1 and SOLO 2 trials (combined N=1,379), dupilumab 300 mg every two weeks produced an IGA 0/1 response in 36-38% of patients versus 8-10% for placebo (P<0.001). 4 The American Academy of Dermatology's 2023 guidelines specifically recommend dupilumab as a first-line systemic agent for adults with moderate-to-severe atopic dermatitis, noting a favorable safety profile compared with cyclosporine and methotrexate. 5

Moderate-to-Severe Asthma With Eosinophilic Phenotype

The FDA approved dupilumab for add-on maintenance therapy in patients aged 6 years and older whose asthma is characterized by an eosinophilic phenotype or who are oral corticosteroid-dependent. Affinity's prior-authorization criteria for this indication typically require evidence of blood eosinophil count of at least 150 cells/mcL or fractional exhaled nitric oxide (FeNO) of at least 25 ppb, plus failure of at least one inhaled corticosteroid/long-acting beta-agonist combination at guideline-recommended doses. 6

Chronic Rhinosinusitis With Nasal Polyps

Dupilumab received FDA approval for add-on maintenance therapy in adults with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in June 2019. 7 Affinity's criteria generally require documentation of bilateral nasal polyps, a Lund-Mackay CT score, prior intranasal corticosteroid use for at least 12 weeks, and often a prior functional endoscopic sinus surgery or documentation of surgical contraindication.

Eosinophilic Esophagitis, Prurigo Nodularis, and Alopecia Areata

These three newer indications (approved 2022 and 2023) may face stricter step-therapy requirements or restricted formulary status depending on the Affinity plan variant. Patients pursuing coverage for alopecia areata, in particular, should expect requests for photographs, a SALT score documenting scalp hair loss of 50% or greater, and documentation that the condition has been present for at least one year. 8

Prior Authorization: Step-by-Step Process

Prior authorization for Dupixent under Affinity Health Plan is managed through their specialty pharmacy and utilization management teams. The process has five predictable stages.

Stage 1: Prescriber Initiates the PA Request

The prescriber (or their office staff) submits a prior-authorization request through Affinity's online portal or by fax to their pharmacy utilization management department. The request must include the patient's diagnosis with ICD-10 code, the proposed dosing regimen, body weight for pediatric patients, documentation of contraindications to step-therapy agents, and the prescriber's NPI number.

Stage 2: Medical Necessity Review

Affinity's pharmacy team reviews the request against their evidence-based criteria. They may request additional records, including office notes, lab results (eosinophil counts, IgE levels), photographs, or specialist letters. Standard review takes up to 3 business days for non-urgent cases and 24-72 hours for expedited reviews when the standard timeline could seriously jeopardize the patient's health. New York State Insurance Law Section 4903 mandates these timelines. 9

Stage 3: Step-Therapy Documentation

Step therapy is the most common source of initial denials. Affinity typically requires evidence that at least one of the following has been tried and failed for the stated minimum duration:

• Topical corticosteroids (class III-VII) for atopic dermatitis, minimum 8 weeks
• Topical calcineurin inhibitors for atopic dermatitis, minimum 8 weeks
• Crisaborole (Eucrisa) for atopic dermatitis, if age-appropriate
• Medium-to-high-dose inhaled corticosteroids plus LABA for asthma
• Intranasal corticosteroid spray for CRSwNP, minimum 12 weeks

The New York Step Therapy Law (enacted 2017) gives prescribers a legal path to override step therapy if it is clinically contraindicated or if the patient already failed those agents. 10 A step-therapy exemption request must be submitted with supporting documentation.

Stage 4: Approval or Denial Notice

If approved, Affinity issues an authorization typically valid for 12 months with a renewal requirement. If denied, the notice must include the clinical reason for denial, the specific criteria not met, and instructions for appeal. Federal regulations under 45 CFR Part 156 require that denial letters be written in plain language. 11

Stage 5: Pharmacy Dispensing

Once authorized, Dupixent is dispensed through a contracted specialty pharmacy. Affinity frequently requires use of a preferred specialty pharmacy network. Patients should confirm which specialty pharmacy is in-network before the prescription is sent, because an out-of-network dispensing event can result in claim rejection even after a valid PA is on file.

How to Appeal a Dupixent Denial

Denials happen. The data show that specialty biologic denials are overturned in roughly 39-50% of first-level appeals when strong clinical documentation is submitted. 12 A structured appeal gives your prescriber the best chance of reversal.

Level 1: Internal Appeal

File within 60 days of the denial notice (New York State standard). The appeal must include a physician letter of medical necessity with specific clinical data (IGA scores, EASI scores for atopic dermatitis; ACQ-5 scores for asthma; SNOT-22 scores for CRSwNP), lab values, photographs where relevant, and the specific policy criterion that was cited as unmet along with counter-evidence.

The treating physician's letter should quote the relevant clinical guideline directly. For atopic dermatitis, the American Academy of Dermatology 2023 guidelines state: "Dupilumab is recommended as a systemic treatment option for adults and children 6 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy." 5

Level 2: External Independent Review

If the internal appeal is denied, New York State law entitles any member to an external appeal reviewed by an independent organization certified by the New York State Department of Financial Services. The external reviewer must issue a decision within 30 business days (or 3 business days for expedited reviews). The decision is binding on the plan. 13

Concurrent Options During the Appeal Process

Patients should simultaneously apply for Sanofi's DUPIXENT MyWay program, which provides the drug at no cost or reduced cost to eligible patients while insurance disputes are resolved. Patients with household incomes at or below 600% of the federal poverty level may qualify for free drug through the patient assistance program. 14

Dupixent Under Affinity Medicaid vs. Essential Plan vs. Qualified Health Plan

The three main product lines at Affinity have meaningfully different coverage rules for specialty biologics.

Affinity Medicaid Managed Care

New York Medicaid covers dupilumab for atopic dermatitis and asthma on its preferred drug list, but prior authorization through eMedNY is still required. Step therapy requirements under Medicaid may be less extensive than commercial plans because New York Medicaid explicitly recognizes dupilumab as a preferred agent for severe atopic dermatitis in adults and children. Out-of-pocket costs are minimal or zero for Medicaid members. 15

Essential Plan

The Essential Plan is a state-subsidized plan for New Yorkers with incomes between 138% and 200% of the federal poverty level. It follows New York Medicaid's clinical coverage policies for specialty drugs, meaning dupilumab PA criteria mirror Medicaid standards. Copayments are capped at a nominal amount by law.

Qualified Health Plans (QHP) on NY State of Health

QHP members face the most complex coverage field. Formulary tier placement, step-therapy requirements, and specialty pharmacy network rules vary by the specific QHP product selected. Members on silver-tier or bronze-tier QHPs may have higher specialty-tier cost sharing before meeting their deductible. Confirming the specific plan's Summary of Benefits and Coverage document is the only reliable way to know the exact out-of-pocket exposure.

Cost-Assistance Options When Coverage Is Denied or Incomplete

Even with coverage, specialty-tier cost sharing can be significant. Several programs reduce out-of-pocket costs substantially.

DUPIXENT MyWay Copay Card

For commercially insured patients (not Medicaid, Medicare, or federal programs), Sanofi's copay card reduces out-of-pocket costs to as low as $0 per month for eligible patients. The card covers up to $13,000 per year in copay assistance. Enrollment takes 5-10 minutes online or by calling 1-844-DUPIXENT. 16

DUPIXENT MyWay Patient Assistance Program

Uninsured patients or those with Medicaid who do not qualify for the copay card may receive Dupixent free through Sanofi's patient assistance program. Eligibility is based on income. Prescribers can initiate enrollment on the patient's behalf.

New York State Pharmaceutical Assistance Programs

New York's EPIC program (Elderly Pharmaceutical Insurance Coverage) covers patients aged 65 and older and may provide supplemental assistance for specialty drugs. The Health Care Reform Act provides additional safety nets for low-income New Yorkers. 17

Manufacturer Bridge Supply

For patients whose PA is under review or appeal, DUPIXENT MyWay can provide a bridge supply of free medication for up to 90 days while the insurance decision is pending. Prescribers must request this directly through the program's case manager.

What the Clinical Data Say About Dupixent's Effectiveness

Insurance requirements for step therapy and prior authorization are grounded (in part) in cost-effectiveness calculations. The clinical evidence for dupilumab, however, is among the strongest in biologic dermatology.

Atopic Dermatitis Trial Data

In the SOLO 1 and SOLO 2 trials (combined N=1,379), dupilumab 300 mg every two weeks produced a 75% or greater reduction in EASI score (EASI-75) in 51% of patients at 16 weeks, versus 15% for placebo (P<0.001). 4 In the LIBERTY AD CHRONOS trial (N=740), the benefit was maintained at 52 weeks with concomitant topical corticosteroids. 18

Asthma Trial Data

In the LIBERTY ASTHMA QUEST trial (N=1,902), dupilumab 200 mg every two weeks reduced severe asthma exacerbations by 47.7% compared with placebo in patients with baseline eosinophil counts of 300 cells/mcL or higher (P<0.001). 6 That magnitude of exacerbation reduction translates directly to reduced emergency department visits, hospitalizations, and oral corticosteroid exposure, arguments your prescriber can include in an appeal letter.

Prurigo Nodularis and Alopecia Areata

In the PRIME and PRIME2 trials (combined N=311), dupilumab produced a 60% reduction in Investigator Global Assessment scores for prurigo nodularis versus 18% for placebo at 24 weeks (P<0.001). 19 For alopecia areata, the REGAIN trial showed a SALT score of 20 or less (representing 80% or greater scalp coverage) in 17% of dupilumab-treated patients versus 3% placebo at 36 weeks. 20 These figures give prescribers concrete endpoints to reference when documenting medical necessity.

Original Decision Framework: Affinity Dupixent Coverage Path

The following four-step framework summarizes the optimal sequence for obtaining Dupixent coverage through Affinity Health Plan, based on the plan's published utilization management criteria and New York State insurance law.

Step 1: Confirm the indication and ICD-10 code. Match the ICD-10 code to an FDA-approved indication before the PA is filed. Mismatched codes are the single most preventable cause of initial denial.

Step 2: Assemble step-therapy documentation before filing. Gather pharmacy records, office notes, and any lab values proving prior treatment trials. Filing a complete record with the initial PA reduces back-and-forth by an average of 7-10 business days in specialty pharmacy workflows. 21

Step 3: File the step-therapy exemption simultaneously if contraindication exists. New York law allows parallel filing of a PA request and a step-therapy exemption. Do not wait for the PA to be denied before asserting the exemption.

Step 4: Enroll in DUPIXENT MyWay on the same day the PA is filed. Bridge supply and copay-card enrollment require no prior approval decision. Enrolling on day one ensures medication access continues uninterrupted if the initial review takes the full 3-business-day window.

Practical Tips for Prescribers Filing Dupixent PAs

A well-constructed prior-authorization request reduces denial rates meaningfully. The following checklist draws on specialty pharmacy best practices and published data on PA outcomes. 12

Documentation Checklist

• Include the EASI, IGA, or SCORAD score at baseline for atopic dermatitis
• Attach pharmacy printouts or EHR records showing dates and durations of prior topical agents
• Note any adverse effects or contraindications to step-therapy drugs (e.g., calcineurin inhibitor contact allergy, ciclosporin nephrotoxicity)
• For pediatric patients, document weight in kilograms for dose confirmation
• Include a sentence explicitly stating the FDA-approved indication and citing the dupilumab prescribing information

Citing Clinical Guidelines in the PA Letter

The American Academy of Dermatology 2023 guidelines are a useful direct quotation for PA letters. The guidelines state that dupilumab "has demonstrated efficacy and an acceptable safety profile in randomized controlled trials of up to 3 years duration" for moderate-to-severe atopic dermatitis. 5 Quoting named guidelines signals to the reviewer that the request is grounded in evidence-based medicine, not off-label use.